From supporting drugs in phases 1 and 2 clinical trials with, for example, integrated evidence generation plans - to multiple commercial launches, support for post-patent-expiry drugs, and successful re-launches.

Deep experience of global market access, with NICE (UK HTA) decision making role of our founder since 2015.

From strategy setting, like global price guidance, launch sequence, to co-developing several tactical brand plans over more than a decade.

Experienced in driving partnership with healthcare systems, clinicians, payers, policymakers, and patients.

Shepherded several pharmaceutical medicines, medical devices, and health technologies from research to market.

Experienced in due-diligence on market potential for new products.

Global projects and customers served.

Depth of experience of working with UK, European, US, Indian, Australian, Canadian, Japanese, Chinese and other healthcare systems context - from national, subnational, to local practice levels.

Skilled in supporting products that are addressing ultra-rare, rare, specialty and tertiary care, secondary care, primary care, or population health and prevention.